CORD Pharmacare Survey

1. CORD Pharmacare Survey
June – September 2018

2. Experience with Current Drug Plan -
NonRare & Rare Disease Patients
With Current Drug Plan my family
has …
Agree
strongly
Agree
somewhat
Neither
agree nor
disagree
Disagree
somewhat
Disagree
strongly
NONRARE Challenges to accessing
needed medicines
40% 21% 15% 13% 10%
RARE Challenges to accessing
needed medicines
66% 12% 1% 3% 18%
NONRARE Been denied
access to necessary drugs due
to cost
30% 15% 17% 9% 28%
RARE Been denied access to
necessary drugs due to cost
51% 7% 12% 4% 25%
NONRARE Concerns about not
accessing new drugs available
elsewhere
66% 23% 9% 0% 2%
RARE Concerns about not
accessing new drugs available
elsewhere
78% 10% 6% 1% 4%
n = 136

3. Current Drug Coverage - All
My family has … Yes No Not Sure
Employer-provided drug plan 70% 30% 1%
Personally paid for private drug plan 35% 65% 1%
Public drug coverage 58% 39% 3%
Very high drug costs covered by
public plan
45% 50% 4%
Been denied drug not on plan's list 55% 37% 8%
Experienced long delays and barriers
to access needed drugs
57% 39% 4%
Been unable to access needed drugs
due to cost or co-pay
41% 54% 5%

4. Current Drug Coverage –
(NonRare & Rare Disease Patients)
My family has … Yes No Not Sure
NONRARE Very high drug costs
covered by public plan
32% 66% 2%
RARE Very high drug costs covered
by public plan
57% 38% 4%
NONRARE Been denied drug not on
plan's list
45% 47% 8%
RARE Been denied drug not on plan's
list
64% 28% 7%
NONRARE Experienced long delays
and barriers to access needed drugs
43% 59% 0%
RARE Experienced long delays and
barriers to access needed drugs
70% 24% 6%

5. Model of Drug Programs - All
35%
25%
37%
24%
23%
19%
20%
21%
19%
10%
18%
8%
15%
14%
17%
Public or Private Choice
1st Private Mandatory
1st Public-Tax Increase
1st Payer – Private or Public
Agree Strongly Agree Somewhat Neither Disagree Somewhat Disagree Strongly

6. Model of Drug Programs
- (NonRare & Rare Disease Patients)
42%
38%
24%
30%
44%
30%
21%
23%
23%
26%
21%
36%
15%
13%
22%
15%
15%
6%
9%
11%
16%
19%
12%
13%
12%
15%
15%
9%
12%
15%
RARE Public or Private Choice
NON Public or Private Choice
RARE 1st Private Mandatory
NON 1st Private Mandatory
RARE 1st Public-Tax Increase
NON 1st Public-Tax Increase
1st Payer – Private or Public
Agree Strongly Agree Somewhat Neither Disagree Somewhat Disagree Strongly

7. Access Innovative Therapies - All
6%
73%
79%
85%
28%
15%
13%
13%
4%
6%
4%
1%
3%
6%
3%
1%
1%
0%
1%
0%
New drugs limited until more evidence
If Terminal - right to try unapproved
Clinicians immed. access new drugs
Potential benefit - monitored access
Patients should have access …
Agree Strongly Agree Some Neutral Disagree Some Agree Strongly2

8. Access to Drug Coverage - All
48%
53%
62%
79%
90%
19%
24%
20%
16%
10%
17%
14%
6%
2%
10%
4%
5%
1%
0%
6%
5%
8%
2%
0%
Supplemental private coverage
Mandatory drug coverage
Provincial additional coverage
Same essential drug list
Public catastrophic coverage
All patients should have access to …
Agree Strongly Agree Some Neutral Disagree Some Disagree Strongly

9. How Should Canada Set Drug Prices? -
All
Canadian Price should …
Agree
strongly
Agree
somewhat
Neither agree
nor disagree
Disagree
somewhat
Disagree
strongly
Promote competition with multiple
suppliers of similar products
70% 20% 8% 1% 0%
Allow Public & Private same price 69% 17% 6% 5% 4%
Include value-added supports and
benefits in pricing
60% 28% 9% 1% 2%
Include societal benefits 52% 24% 12% 4% 8%
Encourage early entry of new
drugs
48% 31% 14% 3% 4%
Reflect economic costs and
benefits
46% 25% 15% 7% 6%
Be at same price as similar GDP
countries
46% 38% 10% 3% 3%
Reflect health outcomes 45% 23% 14% 9% 9%
Recognize global price reflects
country’s GDP
24% 30% 27% 11% 8%